Home spirometry to predict pulmonary exacerbations in CF: fact or fiction?

Home spirometry to predict pulmonary exacerbations in CF: fact or fiction? - Home spirometry in CF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31702

Enrollment

Registered

2008-02-28

Start date

2008-07-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Cystic Fibrosis Able to perform spirometry age 4-18 years old

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Analysis of home measured FEV1 before, during and after a antibiotic treatment (excacerbation). A decrease of 10% or more of the FEV1 compared to the personal best on 3 days in a row, or a decrease wich is slowl progressive in 7 days, and results in a decrease of 10% or more in FEV1 is defined as a clinical relavent decrease in pulmonary function.	—

Countries

Netherlands

Outcome results